Shanghai SIMR Biotechnology Co.,Ltd

中文 | EN

中文 EN

en2023 2022 2021 2020 2019 2018 2017 2016 2015 2014

Home > ABOUT SIMR > Milestones > 2021

2021

en2023 










In October, the second drug candidate, SR1375, successfully completed its first dose group administration in Australia.

发布时间：2022年11月18日

In October, the second drug candidate, SR1375, successfully completed its first dose group administration in Australia.

上一篇：In July, the China IND application for SR419, SIMR Biotech's first analgesic candidate, was approved by the implied license 下一篇：In October, it completed the B+ round financing of nearly RMB200 million led by Zhang Jiang Haocheng and Zhang Jiang Haoheng